Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANHEP: Dalteparin vs Tinzaparin
NCT06020560Phase 4Unknown
- Sponsor
- Herlev Hospital
- Start
- Mar 2023
- Primary completion
- Mar 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in venous thromboembolism (VTE) comparing Dalteparin with Tinzaparin (2 arms). Primary endpoint: 30-day all-cause mortality and bleeding requiring blood transfusion. Status: unknown.
02
Drugs
dalteparintinzaparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06020560.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06020560.